Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment
The German pharmaceutical company Grunenthal GmbH presented the first clinical evidence for the efficacy and
tolerability of tapentadol ER (extended release) for patients suffering from chronic pain at the Annual Congress of the European League Against Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. Tapentadol, a centrally acting analgesic, is the first of its kind, combining two...
First Phase II Short-Term Study on Dapagliflozin Shows Results on
Safety, Tolerability and Glycemic Markers in Subjects With Type 2
Diabetes
-- Additional Findings Reported on Glucose Homeostasis Effects inNormal and Diabetic Rats -- CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day,Phase IIa study of the safety profile of multiple doses of theinvestigational compound dapagliflozin, a selective inhibitor ofthe Sodium-Glucose Transporter 2 (SGLT2) administered alone orconcomitantly with metformin in subjects with Typ...
Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good
Pharmacokinetics and Tolerability in Phase I/II Trial
MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 12, 2007 - GeronCorporation's (Nasdaq:GERN) telomerase inhibitor cancer drug,GRN163L, has demonstrated good pharmacokinetics and
tolerability inits ongoing Phase I/II trial involving patients with chroniclymphocytic leukemia (CLL), according to data presented today byAlan Colowick, M.D., M.P.H., the company's president, oncology, atthe Pan Pacific Ly...
OREXIGEN Therapeutics Announces Sustained-Release Formulation of
Zonisamide Shows Improved Tolerability When Compared to Immediate
Release Formulation
Orexigen(TM) is evaluating zonisamide SR as a novel component inEMPATIC(TM) Phase IIb obesity trial SAN DIEGO, June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)Therapeutics, Inc. , a biopharmaceutical company focused on thetreatment of central nervous system disorders with an initial focuson obesity, today announced results from a Phase I trial evaluatingsafety and pharmacokinetics of...
Vical Interim Clinical Results Demonstrate Safety and Tolerability
of Inovio Biomedical's Electroporation DNA Delivery Technology
SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today that thecompany's partner, Vical Incorporated, presented positive interimsafety and
tolerability data on 18 subjects from an ongoing Phase Iclinical trial...
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in
Phase 2 Trial
EMERYVILLE, Calif., June 04, 2007 /PRNewswire-FirstCall/ --Bionovo, Inc.'s lead drug candidate, MF101, showed positive Phase 2results for the treatment of hot flashes associated with menopause.Two hundred and seventeen women were enrolled in the company'sdouble-blind, placebo- controlled, randomized Phase 2 trial.Postmenopausal women with 50 or more moderate to severe hot flashesper week...
More>>